Amyloid beta-protein (33-42), with the CAS number 178949-81-0, is a peptide fragment derived from the amyloid precursor protein (APP). This peptide consists of 10 amino acids and is part of a larger family of amyloid beta peptides, which are implicated in the pathogenesis of Alzheimer's disease. Characteristically, amyloid beta (Aβ) peptides can aggregate to form oligomers and fibrils, leading to the formation of amyloid plaques in the brains of affected individuals. The 33-42 variant is notable for its hydrophobic properties, which contribute to its aggregation potential. It is often studied for its role in neurotoxicity and synaptic dysfunction associated with Alzheimer's disease. The peptide's structure influences its interaction with neuronal membranes and its ability to disrupt cellular processes. Research continues to explore the mechanisms by which amyloid beta peptides contribute to neurodegeneration, making them a significant focus in the development of therapeutic strategies for Alzheimer's disease.

AMYLOID BETA-PROTEIN (33-42)

178949-81-0: Amyloid beta-protein (33-42), with the CAS number 178949-81-0, is a peptide fragment derived from the amyloid precursor protein (APP). This peptide consists of 10 amino acids and is part of a larger family of amyloid beta peptides, which are implicated in the pathogenesis of Alzheimer's disease. Characteristically, amyloid beta (Aβ) peptides can aggregate to form oligomers and fibrils, leading to the formation of amyloid plaques in the brains of affected individuals. The 33-42 variant is notable for its hydrophobic properties, which contribute to its aggregation potential. It is often studied for its role in neurotoxicity and synaptic dysfunction associated with Alzheimer's disease. The peptide's structure influences its interaction with neuronal membranes and its ability to disrupt cellular processes. Research continues to explore the mechanisms by which amyloid beta peptides contribute to neurodegeneration, making them a significant focus in the development of therapeutic strategies for Alzheimer's disease.

GLMVGGVVIA, a partial sequence of β-amyloid protein which is used for raising antibodies against Aβ 1-42. Li et al. studied the aggregation behavior of this and other Aβ 1-42 C-terminal fragments.

Amyloid β-Protein (33-42)

Please enquire for more information about Amyloid beta-Protein (33-42) trifluoroacetate salt including the price, delivery time and more detailed product information at the technical inquiry form on this page

CAS 178949-81-0

AMYLOID BETA-PROTEIN (33-42)

Amyloid β-Protein (33-42)

Ref: 01-4037474

Amyloid beta-Protein (33-42) trifluoroacetate salt

Ref: 3D-FA109546